Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia

J Clin Oncol. 2013 Sep 1;31(25):e413-6. doi: 10.1200/JCO.2012.47.6770. Epub 2013 Jul 8.

Authors

Brent W Weston¹, Melissa A Hayden, Kathryn G Roberts, Susan Bowyer, Johann Hsu, George Fedoriw, Kathleen W Rao, Charles G Mullighan

Affiliation

¹ The University of North Carolina, Chapel Hill, NC, USA.

PMID: 23835704
DOI: 10.1200/JCO.2012.47.6770

No abstract available

Publication types

Case Reports

MeSH terms

Benzamides / therapeutic use*
Child
Gene Rearrangement
Humans
Imatinib Mesylate
Male
Piperazines / therapeutic use*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyrimidines / therapeutic use*
Receptor, Platelet-Derived Growth Factor beta / genetics
Trans-Activators / genetics

Substances

Benzamides
EBF1 protein, human
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Trans-Activators
Imatinib Mesylate
Protein-Tyrosine Kinases
Receptor, Platelet-Derived Growth Factor beta